Eris Lifesciences partnership with Natco Pharma for Semaglutide launch in India
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
The product will target Type 2 diabetes management aligning with unmet needs in India’s expanding metabolic care landscape
One of India’s top integrated contract research, development, and manufacturing organizations (CRDMOs) is on a hiring spree
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
The project entails a total planned capital expenditure of approximately Rs. 500 - 520 crore
The alliance directly links VivaMed’s computational drug hypotheses with Syngene’s preclinical development capabilities
This multi-year CDMO agreement involves significant, ongoing manufacturing for a global pharmaceutical major
Our vision is to position India not just as a consumer of advanced simulation technologies but as a creator and exporter of them
Expansion at the Oss (NL) site adds capacity and R&D capabilities, supporting the development and manufacturing of ADCs and other novel bioconjugates from First-in-Human to commercialization
40+ most innovative startups with disruptive contributions across MedTech, Medical Devices, BioPharma, Cell and Gene Therapy, AI and ML, Nutraceuticals, and Biomarkers exhibited their cutting-edge solutions
Subscribe To Our Newsletter & Stay Updated